This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.In the United States, in 2001, the incidence of cancer was 16.5 per 100,000 children aged 0 - 19 years. In general, solid tumors account for approximately 30% of cases of childhood cancers. These tumors are unique with the respect to their responsiveness to many chemotherapeutic agents. However, the prognosis is very poor for pediatric patients with solid tumors which are refractory to previous chemotherapy. Irinotecan has been studied extensively in the population and has demonstrated activity across a range of doses and regimens with manageable toxicities. Although cetuximab has not been studied in the pediatric population, based on its favorable safety profile in adults, no severe toxicities are expected. In addition, given its demonstrated efficacy in a variety of adult tumors, it is likely that activity will be seen in some pediatric malignancies as well. Thus, given the poor prognosis of these patients, it is expected that the benefit of studying this combination in pediatric patients with refractory solid tumors will be far greater than the risks.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000082-45
Application #
7605502
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2006-12-23
Project End
2007-11-30
Budget Start
2006-12-23
Budget End
2007-11-30
Support Year
45
Fiscal Year
2007
Total Cost
$9,058
Indirect Cost
Name
University of Florida
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Mangal, Naveen; James, Margaret O; Stacpoole, Peter W et al. (2018) Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children. J Clin Pharmacol 58:212-220
Boissoneault, Jeff; Letzen, Janelle; Lai, Song et al. (2016) Abnormal resting state functional connectivity in patients with chronic fatigue syndrome: an arterial spin-labeling fMRI study. Magn Reson Imaging 34:603-8
Shumyak, Stepan; Yang, Li-Jun; Han, Shuhong et al. (2016) ""Lupoid hepatitis"" in SLE patients and mice with experimental lupus. Clin Immunol 172:65-71
Hendeles, Leslie; Khan, Yasmeen R; Shuster, Jonathan J et al. (2015) Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 114:58-62.e2
Price, Catherine C; Levy, Shellie-Anne; Tanner, Jared et al. (2015) Orthopedic Surgery and Post-Operative Cognitive Decline in Idiopathic Parkinson's Disease: Considerations from a Pilot Study. J Parkinsons Dis 5:893-905
Krueger, Charlene A; Cave, Emily C; Garvan, Cynthia (2015) Fetal response to live and recorded maternal speech. Biol Res Nurs 17:112-20
Jones, Jacob D; Marsiske, Michael; Okun, Michael S et al. (2015) Latent growth-curve analysis reveals that worsening Parkinson's disease quality of life is driven by depression. Neuropsychology 29:603-9
Morishita, Takashi; Foote, Kelly D; Archer, Derek B et al. (2015) Smile without euphoria induced by deep brain stimulation: a case report. Neurocase 21:674-8
Del-Aguila, J L; Cooper-DeHoff, R M; Chapman, A B et al. (2015) Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. Pharmacogenomics J 15:153-7
Chapman, Arlene B; Cotsonis, George; Parekh, Vishal et al. (2014) Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension. Am J Hypertens 27:546-54

Showing the most recent 10 out of 266 publications